Intravitreal Bevacizumab for Diabetic Papillopathy

dc.contributor.authorÖrnek, Kemal
dc.contributor.authorOğurel, Tevfik
dc.date.accessioned2020-06-25T17:51:16Z
dc.date.available2020-06-25T17:51:16Z
dc.date.issued2010
dc.departmentKırıkkale Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü
dc.description.abstractA 43-year-old woman presented with a visual acuity of 1/10 in the right eye and 3/10 in the left eye. Ophthalmologic examination disclosed optic disc swelling on both sides with mild nonproliferative diabetic retinopathy. The pupils were equal and reactive without an afferent pupillary defect. Visual field testing showed no significant defect in both eyes. Systemic investigations revealed no abnormality. The patient was injected with bevacizumab intravitreally with the diagnosis of diabetic papillopathy (DP). Three weeks later, the vision increased to 7/10 in the right eye and optic disc edema disappeared. Intravitreal injection of bevacizumab effectively treated DP.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1089/jop.2009.0125
dc.identifier.endpage218en_US
dc.identifier.issn1080-7683
dc.identifier.issn1557-7732
dc.identifier.issue2en_US
dc.identifier.pmid20334555
dc.identifier.scopus2-s2.0-77951693533
dc.identifier.scopusqualityQ1
dc.identifier.startpage217en_US
dc.identifier.urihttps://doi.org/10.1089/jop.2009.0125
dc.identifier.urihttps://hdl.handle.net/20.500.12587/4767
dc.identifier.volume26en_US
dc.identifier.wosWOS:000276990000014
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMary Ann Liebert, Incen_US
dc.relation.ispartofJournal Of Ocular Pharmacology And Therapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleIntravitreal Bevacizumab for Diabetic Papillopathyen_US
dc.typeArticle

Dosyalar